Company / R&D per Share
Jazz Pharmaceuticals R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$12.91
FY2025
5-year range
$5.34 / $14.20
FY2021-FY2025
Trend
-9.1%
vs FY2024
Sector context
#12 of 208
Health Care
What the data says
Among 208 Health Care companies, Jazz Pharmaceuticals is in the top 6% for r&d per share. R&D per Share has fluctuated over the past 10 years, ranging from $1.39 in FY2016 to $14.20 in FY2024.
Based on SEC 10-K filings.
12.91 in FY2025 with a 5-year CAGR of +26.2%. Top quartile in the Health Care sector.
Declined from $13.44 to $12.91 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +33.4%
- 5-Year CAGR
- +26.2%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 208This company $12.91 Sector average $12.19
▼
+5.9% above sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 9.1% year-over-year.
- Ranks #12 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2024.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.91 | -9.1% |
| FY2024 | $14.20 | +5.6% |
| FY2023 | $13.44 | +147.0% |
| FY2022 | $5.44 | +2.0% |
| FY2021 | $5.34 | +32.2% |
| FY2020 | $4.04 | +17.4% |
| FY2019 | $3.44 | +24.8% |
| FY2018 | $2.76 | -16.9% |
| FY2017 | $3.32 | +138.7% |
| FY2016 | $1.39 | -37.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026